ArticleBulletin of experimental biology and medicine2026
GRO‑α Promotes the Proliferation and Migration of Triple-Negative Breast Cancer Cells through AKT-mTOR Signaling Pathway.
Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth-regulated oncogene‑α (GRO‑α) has been widely reported in tumorigenesis. However, the specific contribution of GRO‑α to the malignant behaviors of triple-negative breast cancer (TNBC) remains unclear. Bioinformatics analyses were conducted using the UALCAN and TIMER databases. The underlying mechanism of action of GRO‑α on the progression of TNBC MDA-MB-231 cells was investigated using CCK‑8, EdU, transwell and Western blotting assays. TNBC tissues exhibited elevated expression of GRO‑α, and its high expression was positively correlated with tumor immune cytokines and immune cell recruitment. The growth and migration of TNBC MDA-MB-231 cells were significantly enhanced following treatment with recombinant GRO‑α. Consistently, the protein levels of AKT, p‑mTOR, and mTOR in MDA-MB-231 cells were extremely elevated by recombinant GRO‑α. In addition, the malignant behaviors induced by GRO‑α were surprisingly attenuated following treatment with mTOR inhibitor Torin1. GRO‑α may play a role in the malignant progression of TNBC in an AKT-mTOR-dependent manner.
Indexed as
Identifiers
42230497What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.